U.S. markets closed

Heat Biologics, Inc. (HTBX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
7.42+0.09 (+1.23%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close7.33
Open7.39
Bid7.49 x 800
Ask7.40 x 1200
Day's Range7.23 - 7.54
52 Week Range3.50 - 30.10
Volume244,703
Avg. Volume2,441,562
Market Cap188.543M
Beta (5Y Monthly)0.32
PE Ratio (TTM)N/A
EPS (TTM)-1.63
Earnings DateAug 07, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • ACCESSWIRE

    Heat Biologics Provides Year-End Business Update

    DURHAM, NC / ACCESSWIRE / March 25, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today provided financial, clinical and operational updates for the year ended December 31, 2020.

  • ACCESSWIRE

    Heat Biologics to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

    DURHAM, NC / ACCESSWIRE / March 8, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced that Jeff Wolf, CEO of Heat Biologics, has been invited to present at Inaugural Emerging Growth Virtual Conference, hosted by M Vest LLC and Maxim Group LLC.

  • HTBX: HS-110 Phase 2 Interim Data
    Zacks Small Cap Research

    HTBX: HS-110 Phase 2 Interim Data

    By John Vandermosten, CFA NASDAQ:HTBX READ THE PREVIOUS HTBX RESEARCH REPORT HS-110 Interim Data Heat Biologics, Inc. (NASDAQ:HTBX) announced positive interim survival data for its Phase II trial of HS-110 (viagenpumatucel-L), a cell-based therapy, in combination with leading checkpoint blockade inhibitors (CBIs). The trial was not a comparator trial; however, similarities in design with past